RENACIDIN IRRIGATION Rx
Generic Name and Formulations:
Citric acid 6.602g, glucono-delta-lactone 198mg, magnesium carbonate 3.177g; per 100mL; irrigation soln (pH 3.85).
Indications for RENACIDIN IRRIGATION:
Dissolution of renal or bladder calculi composed of apatite or struvite in select patients. Adjunct to dissolve apatite or struvite calculi after surgery or to achieve partial dissolution prior to surgical removal. Prevention of incrustations of indwelling urinary tract catheters.
Renal calculi: Irrigate with sterile saline at 60mL/hr after fourth or fifth post-operative day and increase until pain, elevated pressure or a maximum of 120mL/hr is achieved; then start Renacidin at max rate achieved with saline. Bladder calculi: 30mL through urinary catheter into bladder, clamp for 30–60 minutes, drain bladder; repeat 4–6 times a day. Catheter incrustation: 30mL through catheter, clamp for 10 minutes, drain; repeat 3 times daily.
UTIs (obtain urine culture prior to use). Urinary tract extravasation.
Monitor magnesium, phosphate, serum creatinine, intrapelvic pressure, and for UTI or catheter obstruction; discontinue if these increase or severe urothelial edema on X-ray occur. Impaired renal function. Maintain catheter patency. Elderly. Pregnancy (Cat.C). Nursing mothers.
Concomitant magnesium: not recommended.
Transient flank pain, urthelial ulceration and/or edema, fever, UTI, back pain, dysuria, transient hematuria, nausea, hypermagnesemia, hyperphosphatemia, elevated serum creatinine, candidiasis, bladder irritation.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally